Pharmaceuticals
Foresee Pharmaceuticals Announces Completion of US$47 Million Financing
TAIPEI, Dec. 24, 2020 /PRNewswire/ -- Foresee pharmaceuticals (TPEx: 6576.TWO) ("Foresee") announces that it has successfully completed an underwritten public offering of 15,000,000 shares of its common stock to the public at a price of NT$88 per share. The aggregate gross proceeds to Foresee from...
2020-12-24 18:00
10505
Senhwa Biosciences Receives US FDA 'Study May Proceed' Letter to Treat BRCA2+ or PALB2+ Solid Tumors With CX-5461
TAIPEI and SAN DIEGO, Dec. 23. 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that it has received a "Study May Proceed" letter fr...
2020-12-24 10:40
2879
Conbercept: New Generation of Product for Treatment of nAMD Completes 36-week Primary Endpoint Visits of Phase III Trial
CHENGDU, China, Dec. 23, 2020 /PRNewswire/ -- Chengdu Kanghong Pharmaceutical Group ("Kanghong") announced a key development milestone of its key product conbercept last month. Kanghong is seeking global approval of conbercept by undertaking a multicenter, multinational, double-masked, parallel-gr...
2020-12-23 22:40
6301
I-Mab Announces Upcoming Participation at January Conferences
SHANGHAI and GAITHERSBURG, Md., Dec. 23, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in Januar...
2020-12-23 21:00
5753
Hyundai Bioscience Develops Injection Drug for Potential Treatment of Severe Cases of COVID-19
SEOUL, South Korea, Dec. 22, 2020 /PRNewswire/ -- Hyundai Bioscience (KOSDAQ symbol: 048410) announced on the 23rd, December 2020, that CNPharm, its major shareholding bio tech company, has succeeded in developing 'Poly-COV01,' an injection drug for thepotential treatment of patients with severe ...
2020-12-23 10:09
1682
Pierre Fabre Selects AGC Biologics as CDMO to manufacture the orphan drug ER-004
SEATTLE, Dec. 21, 2020 /PRNewswire/ -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced its partnership with Laboratoire Pierre Fabre to manufacture ER-004 – an intra-amniotic drug that will pioneer the treatment of a rare and...
2020-12-21 23:00
1602
Longevity Acquisition Corporation Announces 4D pharma Joining Landmark Parkinson's Progression Markers Initiative
NEW YORK, Dec. 21, 2020 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that onDecember 18, 2020, 4D pharma plc (AIM: DDDD) ("4D pharma"), a pharmaceutical company leading the development of L...
2020-12-21 21:00
10880
ImmuneMed's hzVSF-v13, COVID-19 clinical trials accelerate development of the treatment
Followed by Russia, Indonesia, and Korea, the second phase of the COVID-19 clinical trial was approved inItaly on Friday, December 18, 2020. CHUNCHEON, South Korea, Dec. 20, 2020 /PRNewswire/ -- The broad spectrum antiviral therapeutic, 'hzVSF-v13(humanized Virus Suppressing Factor)' being devel...
2020-12-21 10:43
1173
Teijin Pharma and TransThera Biosciences Form Strategic R&D Collaboration
TOKYO and NANJING, China, Dec. 18, 2020 /PRNewswire/ -- Teijin Pharma Limited
2020-12-18 23:30
3469
Clarity Pharmaceuticals closes $25m capital raising
SYDNEY, Dec. 15, 2020 /PRNewswire/ -- Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has completed a capital raising of$25,000,410. Dr Alan Taylor, Executive Chairman of Clarity Pharmaceuticals, co...
2020-12-15 22:12
2086
GMAX Zhengzhou Manufacturing Site Breaks Ground
HANGZHOU, China, Dec. 15, 2020 /PRNewswire/ -- Gmax Biopharm today holds ground-breaking ceremony for itsZhengzhou, China manufacturing site which is the production base for its GMA102 (T2D), GMA105 (obesity), and GMA301A/B (PAH for adult and children) drugs to be launched between 2023-2025, upon...
2020-12-15 18:00
1279
Sunshine Guojian Selects Verseau's VSIG4-targeted Antibody as the Second Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration
SHANGHAI, Dec. 14, 2020 /PRNewswire/ -- 3SBio Inc. ("3SBio")'s subsidiary,
Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd. ("Sunshine Guojian") and
Verseau Therapeutics, Inc.
2020-12-14 22:28
1889
I-Mab Added to Nasdaq Biotechnology Index
SHANGHAI and GAITHERSBURG, Md., Dec. 14, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab's American Depositary Shares (ADS) have been ...
2020-12-14 21:00
8751
PharmAbcine presents the latest data of the ongoing Phase Ib mTNBC trial at SABCS 2020
DAEJEON, South Korea, Dec. 9, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today the presentation of the latest interim data from its ongoing phase Ib combination trial of oli...
2020-12-09 23:00
1477
Through Strategic Collaboration with GenScript ProBio, Initium Therapeutics Plans to Utilize GenScript ProBio's Berkeley Lights Beacon Platform to Expand Their Antibody Drug Pipeline
NANJING, China, Dec. 7, 2020 /PRNewswire/ -- On December 7, 2020, GenScript ProBio and Initium Therapeutics announced that Initium Therapeutics has launched a single B-cell based antibody development platform through collaboration with GenScript ProBio. Initium Therapeutics is a US biotechnology ...
2020-12-07 22:00
1588
PharmAbcine to present new interim data from its ongoing mTNBC trial at SABCS 2020
DAEJEON, South Korea, Dec. 7, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today that the company will present the updated interim data from the ongoing phase Ib trial of olin...
2020-12-07 21:00
1236
CARsgen Therapeutics Presents Updated Multiple Myeloma Cell Therapy Data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition
SHANGHAI, Dec. 6, 2020 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage biopharmaceutical company, announced updated safety and efficacy results from its ongoing global clinical studies of CT053, an investigational chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed an...
2020-12-06 19:00
3690
I-Mab Accelerates Clinical Development of Anti-CD47 Monoclonal Antibody Lemzoparlimab in the US and China
SHANGHAI and GAITHERSBURG, Md., Dec. 4, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics, today announced the advancement of clinical dev...
2020-12-04 21:00
8358
Samsung Biologics drives digital transformation with Plant 4 Virtual Showroom launch
INCHEON, South Korea, Dec. 4, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced the launch of a virtual showroom to provide key features and real-time construction updates of its recently announced Plant 4. The digital showcase also highlights various specs and services that the S...
2020-12-04 20:00
2324
Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for COVID-19
Highlights: * The first hospitalized patient with severe COVID-19, treated under an eIND was discharged in 5 days after being treated with Silmitasertib. * The first patient with moderate COVID-19 has enrolled into this clinical trial at the Center for Advanced Research and Education (CARE),G...
2020-12-03 22:17
2409
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
8546
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7700